170 related articles for article (PubMed ID: 38299551)
1. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis.
Thng ZX; Regenold J; Bromeo AJ; Akhavanrezayat A; Than NTT; Khatri A; Mohammadi SS; Tran ANT; Shin YU; Karaca I; Ghoraba HH; Or CCM; Nguyen QD
Expert Opin Investig Drugs; 2024 Feb; 33(2):95-104. PubMed ID: 38299551
[TBL] [Abstract][Full Text] [Related]
2. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.
Gupta S; Shyamsundar K; Agrawal M; Vichare N; Biswas J
J Ocul Pharmacol Ther; 2022 Apr; 38(3):203-222. PubMed ID: 35133890
[TBL] [Abstract][Full Text] [Related]
3. Update on the systemic management of noninfectious uveitis in children and adolescents.
Leal I; Steeples LR; Wong SW; Giuffrè C; Pockar S; Sharma V; Green EKY; Payne J; Jones NP; Chieng ASE; Ashworth J
Surv Ophthalmol; 2024; 69(1):103-121. PubMed ID: 36682467
[TBL] [Abstract][Full Text] [Related]
4. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
[TBL] [Abstract][Full Text] [Related]
5. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
Thomas AS
Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
[TBL] [Abstract][Full Text] [Related]
6. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
[No Abstract] [Full Text] [Related]
7. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
[No Abstract] [Full Text] [Related]
8. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.
Liu W; Bai D; Kou L
BMC Ophthalmol; 2023 May; 23(1):240. PubMed ID: 37248486
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab in the treatment of non-infectious uveitis.
Burek-Michalska A; Turno-Kręcicka A
Adv Clin Exp Med; 2020 Oct; 29(10):1231-1236. PubMed ID: 33125196
[TBL] [Abstract][Full Text] [Related]
10. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars.
Prignano F; Choi J; Pieper B; Iversen L
Expert Opin Biol Ther; 2021 Jan; 21(1):75-80. PubMed ID: 32886008
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis-Related Uveitis in Patients under Anti-TNF-alpha Therapy: A Case Series.
Hernanz I; Miguel Escuder L; Chamorro L; Moll-Udina A; Espinosa G; Sainz de la Maza M; Llorenç V; Adán A
Ocul Immunol Inflamm; 2022 May; 30(4):839-844. PubMed ID: 33216652
[TBL] [Abstract][Full Text] [Related]
14. Biotherapies in Uveitis.
Leclercq M; Desbois AC; Domont F; Maalouf G; Touhami S; Cacoub P; Bodaghi B; Saadoun D
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33171664
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis.
Tai F; Mehraban Far P; Pechlivanoglou P; Ramsay LC; Georgakopoulos JR; Sander B; Derzko-Dzulynsky LA; Felfeli T
Ophthalmology; 2022 Mar; 129(3):357-359. PubMed ID: 34634363
[No Abstract] [Full Text] [Related]
16. Safety of systemic therapy for noninfectious uveitis.
Ormaechea MS; Hassan M; Onghanseng N; Park JH; Mahajan S; Al-Kirwi KY; Uludag G; Halim MS; Schlaen A; Sepah YJ; Do DV; Nguyen QD
Expert Opin Drug Saf; 2019 Dec; 18(12):1219-1235. PubMed ID: 31801415
[No Abstract] [Full Text] [Related]
17. Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.
Thng ZX; Bromeo AJ; Mohammadi SS; Khatri A; Tran ANT; Akhavanrezayat A; T T Than N; Nguyen KS; Yoo WS; Mobasserian A; Or CCM; Nguyen QD
Expert Opin Emerg Drugs; 2023 Dec; 28(4):297-309. PubMed ID: 38129984
[TBL] [Abstract][Full Text] [Related]
18. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
[TBL] [Abstract][Full Text] [Related]
19. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis.
Bellur S; McHarg M; Kongwattananon W; Vitale S; Sen HN; Kodati S
JAMA Ophthalmol; 2023 Feb; 141(2):150-156. PubMed ID: 36547953
[TBL] [Abstract][Full Text] [Related]
20. The current status of biological treatment for uveitis.
Gaggiano C; Sota J; Gentileschi S; Caggiano V; Grosso S; Tosi GM; Frediani B; Cantarini L; Fabiani C
Expert Rev Clin Immunol; 2020 Aug; 16(8):787-811. PubMed ID: 32700605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
